Fig. 5: P4HB is targetable by securinine repurposing and may act as a blood diagnostic biomarker for GBM progression. | Oncogenesis

Fig. 5: P4HB is targetable by securinine repurposing and may act as a blood diagnostic biomarker for GBM progression.

From: P4HB maintains Wnt-dependent stemness in glioblastoma stem cells as a precision therapeutic target and serum marker

Fig. 5

A, B Cell proliferation assays for X01 (A) and 448 (B) GSCs treated with P4HB inhibitor securinine in a dose-dependent manner. Data are presented as means ± SD, n = 4, no significant (ns), *P < 0.05, **P < 0.01, ***P < 0.001, t-test. C Kaplan–Meier survival curves of mice implanted with X01 GSCs treated with Control or securinine (n = 6 in each group, 1 × 105 GSCs/mouse, 15 mg/kg, I.P. injection), P = 0.0089, log-rank test. D H&E staining of the whole brains of mice bearing orthotopic xenografts of X01 GSCs treated with securinine, scale bar, 50 μm. E Schematic diagram of the high level of intracellular P4HB secreted into blood vessels. F, G Measurement of the serum protein level of P4HB in GBM patients and healthy controls from Henan Provincial People’s Hospital and Chinese PLA General Hospital in Beijing. ***P < 0.001, t-test. H Comprehensive overview of P4HB roles in GSCs tumorigenesis and its secretion into blood vessels as a diagnostic biomarker in GBM patients.

Back to article page